U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

This article is a text version of a Wall Street Journal newsletter published earlier today.

Pleas note: we will be discontinuing the Global Markets Report after 28 February. Australian shares are set to open lower, ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the stock market. When investing, your capital is at risk. The value of your ...

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

CRISPR Therapeutics and Vertex Pharmaceuticals ... the keys to navigating this complex but rewarding sector. 3 Source: Ben Fidler, "Three biotechs raise $700M in Rare burst of IPO activity ...

Ben Ray Luján (D-N.M.) on Wednesday ... OPIOID ALTERNATIVE APPROVAL — On Thursday, the FDA approved Vertex Pharmaceuticals’ nonopioid pain reliever to treat moderate-to-severe acute pain ...

Franklin Resources (BEN) was the top performer in the S ... and raised its long-term sales outlook for the drugs. Vertex Pharmaceuticals (VRTX) moved up by 5.3% after it said that the Food and ...

Detailed price information for Microchip Technology (MCHP-Q) from The Globe and Mail including charting and trades.

This afternoon, the S&P 500 Index ($SPX) (SPY) is down -0.48%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.71%, and the Nasdaq 100 Index ($IUXX) (QQQ) is ...

However, as Ben Hargreaves discovers ... pharmaphorum reached out to Vertex Pharmaceuticals to learn more about its general development process and specifically why rare diseases present such ...